IP Library Granted Patent US 7,871,639
Granted Patent B2
US 7,871,639 · App. 11/877,396 · Granted Jan 18, 2011

Biocompatible phase invertable proteinaceous compositions and methods for making and using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,871,639
App. No.
11/877,396
Granted
Jan 18, 2011
Kind
B2
Abstract

Biocompatible phase invertable proteinaceous compositions and methods for making and using the same are provided. The subject phase invertable compositions are prepared by combining a proteinaceous substrate and a cross-linker. The proteinaceous substrate includes one or more proteins and an adhesion modifier, and may also include one or more of: a plasticizer, a carbohydrate, or other modification agent. In certain embodiments, the cross-linker is a heat-treated dialdehyde, e.g., heat-treated glutaraldehyde. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.

Claims (36)

1. A method of producing a phase invertable composition, said method comprising:

combining:

(a) a substrate comprising a proteinaceous material; and

(b) a heat-stabilized aldehyde crosslinking agent that has been produced by maintaining an initial aldehyde crosslinking composition at an elevated temperature that ranges from about 45 to about 55° C. for a period of time that ranges from about 1 to about 20 days;

to produce said phase invertable composition.

2. The method according to claim 1 , wherein said proteinaceous material comprises one or more of: albumin, elastin, fibrin and soluble and insoluble forms of collagen and combinations thereof.

3. The method according to claim 1 , wherein said substrate further comprises an adhesion modifier.

4. The method according to claim 3 , wherein said adhesion modifier is chosen from polyethyleneimine, gelatin and carboxymethylcellulose.

5. The method according to claim 1 , wherein said substrate further comprises a plasticizer.

6. The method according to claim 5 , wherein the plasticizer is chosen from polyethylene glycol, glycerin, a fatty acid, butylhydroxytoluene, and combinations thereof.

7. The method according to claim 1 , wherein said substrate further comprises a carbohydrate.

8. The method according to claim 1 , wherein said substrate further comprises a filler.

9. The method according to claim 1 , wherein said substrate further comprises a polyblend of one or more modifying polymers.

10. The method according to claim 1 , wherein said substrate further comprises a biologically active agent.

11. The method according to claim 1 , wherein said substrate further comprises a foaming agent.

12. The method according to claim 1 , wherein said heat-stabilized aldehyde crosslinking agent comprises heat-stabilized glutaraldehyde.

13. A method of placing a biocompatible composition to a site of a subject, said method comprising:

(a) preparing a phase invertable composition by combining:

(i) a substrate comprising a proteinaceous material; and

(ii) a heat-stabilized aldehyde crosslinking agent that has been produced by maintaining an initial dialdehyde crosslinking composition at an elevated temperature that ranges from about 45 to about 55° C. for a period of time that ranges from about 1 to about 20 days;

to produce said phase invertable composition; and

(b) introducing said phase invertable composition to said site of said subject.

14. The method according to claim 13 , wherein said phase invertable composition is prepared at a site external to said subject.

15. The method according to claim 13 , wherein said phase invertable composition is prepared at said site.

16. A kit for producing a phase invertable composition, said kit comprising:

(a) a substrate comprising a proteinaceous material;

(b) a heat-stabilized aldehyde crosslinking agent that has been produced by maintaining an initial dialdehyde crosslinking composition at an elevated temperature that ranges from about 45 to about 55° C. for a period of time that ranges from about 1 to about 20 days.

17. The kit according to claim 16 , wherein said kit further comprises a phase invertable fluid delivery device.

18. The method according to claim 1 , wherein the heat stabilized aldehyde crosslinking agent comprises a heat stabilized dialdehyde.

19. A method of producing a phase invertible composition, said method comprising:

combining:

(a) a substrate comprising a proteinaceous material; and

(b) a heat-stabilized aldehyde crosslinking agent that produces pyridinium crosslinks of proteins of the proteinaceous material;

to produce said phase invertable composition.

20. The method according to claim 19 , wherein the heat stabilized aldehyde crosslinking agent comprises a heat stabilized dialdehyde.

21. The method according to claim 19 , wherein said heat-stabilized aldehyde crosslinking agent comprises heat-stabilized glutaraldehyde.

Assignments (5)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 043596, FRAME 0259 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2018
From: MATRIX MEDICAL, LLC
To: TENAXIS MEDICAL, INC.
Reel/Frame 046004/0072 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2018
From: MALLINCKRODT PHARMA IP TRADING DAC
To: BAXTER INTERNATIONAL, INC.
Reel/Frame 045754/0904 →
NUNC PRO TUNC ASSIGNMENT Recorded Oct 3, 2017
From: TENAXIS MEDICAL, INC.
To: MALLINCKRODT PHARMA IP TRADING D.A.C.
Reel/Frame 043767/0923 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Aug 18, 2017
From: MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 043596/0259 →